Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14941503 | 0.82 | NNMT (0.34) | NNMTKAT2BBRD9LRRK2ALDH1A1 | |
| SCHEMBL12439072 | 0.80 | ALDH1A1 (0.36) | NNMTKAT2BBRD9LRRK2ALDH1A1 | |
| SCHEMBL1872686 | 0.78 | KAT2B (0.32) | KAT2BBRD9 | |
| SCHEMBL15173500 | 0.78 | TDP1 (0.35) | NNMTKAT2BBRD9ALDH1A1KDM4E | |
| SCHEMBL31257580 | 0.78 | TDP1 (0.35) | NNMTKAT2BBRD9ALDH1A1KDM4E | |
| SCHEMBL15431221 | 0.77 | CHRNB2 (0.31) | — | |
| SCHEMBL16187963 | 0.76 | ALDH1A1 (0.36) | NNMTKAT2BBRD9LRRK2ALDH1A1 | |
| SCHEMBL24713406 | 0.75 | GABRA1 (0.32) | KAT2BBRD9LMNA | |
| SCHEMBL18504878 | 0.74 | APP (0.33) | NNMTKAT2BBRD9ALDH1A1KDM4E | |
| SCHEMBL14941507 | 0.74 | NNMT (0.33) | NNMTKAT2BBRD9ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3089971-B1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| CN-109045032-A | Aminopyridines and application method | 麦迪威森技术有限责任公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-106132950-B | Aminopyridines and methods of use | 麦迪威森技术有限责任公司 | 2018-11-09 | — | — | CN | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| CN-106132950-A | Compounds and methods of use | 麦迪韦逊技术股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| US-20160326137-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2016-11-10 | — | — | US | disclosed |
| EP-3089971-A1 | COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015103355-A1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | NNMT 278/4885KAT2B 721/4885BRD9 2503/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | NNMT 278/4885KAT2B 721/4885BRD9 2503/4885 |
| US-10030004-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | NNMT 278/4885KAT2B 721/4885BRD9 2503/4885 |
| US-20160326137-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | NNMT 278/4885KAT2B 721/4885BRD9 2503/4885 |
| US-20200071296-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | NNMT 278/4885KAT2B 721/4885BRD9 2503/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | NNMT 278/4885KAT2B 721/4885BRD9 2503/4885 |
| US-20180208577-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | NNMT 278/4885KAT2B 721/4885BRD9 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.